Cubist Systematic Strategies, LLC Vertex Pharmaceuticals Inc Transaction History

Cubist Systematic Strategies, LLC

$15.8 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $2.23 Million - $2.44 Million	5,469 Added 22.36%	29,923 $12.5 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $1.99 Million - $2.38 Million	-5,807 Reduced 19.19%	24,454 $9.95 Million
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $339,532 - $363,909	-1,004 Reduced 3.21%	30,261 $10.5 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $5.66 Million - $6.34 Million	18,016 Added 135.98%	31,265 $11 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $23 Million - $26.2 Million	-81,146 Reduced 85.96%	13,249 $4.17 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $2.4 Million - $2.7 Million	8,404 Added 9.77%	94,395 $27.3 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $2.88 Million - $3.21 Million	10,501 Added 13.91%	85,991 $24.9 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $2.6 Million - $3.24 Million	-11,084 Reduced 12.8%	75,490 $21.3 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $12.1 Million - $14.3 Million	54,686 Added 171.49%	86,574 $22.6 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $1.05 Million - $1.32 Million	-5,921 Reduced 15.66%	31,888 $7 Million
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $9.83 Million - $11 Million	-54,190 Reduced 58.9%	37,809 $6.86 Million
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $8.41 Million - $9.92 Million	-44,859 Reduced 32.78%	91,999 $18.6 Million
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $23.8 Million - $27.8 Million	115,145 Added 530.3%	136,858 $29.4 Million
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $1.64 Million - $2.18 Million	-7,909 Reduced 26.7%	21,713 $5.13 Million
Q3 2020 Nov 16, 2020	BUY	$255.65 - $303.1 $5.45 Million - $6.46 Million	21,307 Added 256.25%	29,622 $8.06 Million
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $1.37 Million - $1.8 Million	6,088 Added 273.37%	8,315 $2.41 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $13.9 Million - $17.2 Million	-69,391 Reduced 96.89%	2,227 $530,000
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $10.3 Million - $13.9 Million	61,975 Added 642.69%	71,618 $15.7 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $930,555 - $1.05 Million	5,598 Added 138.39%	9,643 $1.63 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $3.22 Million - $3.72 Million	-19,566 Reduced 82.87%	4,045 $742,000
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $806,697 - $959,286	4,927 Added 26.37%	23,611 $4.34 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $1.8 Million - $2.28 Million	11,849 Added 173.36%	18,684 $3.1 Million
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $6.78 Million - $7.79 Million	-40,408 Reduced 85.53%	6,835 $1.32 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $6.17 Million - $7.2 Million	42,349 Added 865.32%	47,243 $8.03 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $387,034 - $452,212	2,553 Added 109.06%	4,894 $798,000
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $2.19 Million - $2.48 Million	-15,957 Reduced 87.21%	2,341 $351,000
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $2.71 Million - $2.97 Million	18,298	18,298 $2.78 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$10.9 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$9.45 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$8.7 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$4.82 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$3.67 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account